JERUSALEM, April 1 (Xinhua) -- Israel's Teva Pharmaceutical, the world's largest generic drugmaker announced on Monday that the European Commission has granted the marketing authorization for Ajovy, Teva's injection drug for the treatment of migraine.
Migraine is the most prevalent neurological disorder affecting more than 50 million people in Europe and 1 billion people worldwide.
Ajovy is indicated for the prevention of migraine in adults who suffer at least four days of migraine per month.
The drug is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Teva noted that Ajovy is the first and only anti-CGRP drug approved in the EU and the United States that is designed for the prevention of migraine that offers both quarterly and monthly dosing options.
The drug was approved for use in the United States in last September. Teva expects that in 2019, sales of the drug in the United States will worth 150 million U.S. dollars.
